1186335-65-8Relevant articles and documents
Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide
Iwai, Yuma,Takahashi, Hitoshi,Hatakeyama, Dai,Motoshima, Kazunori,Ishikawa, Minoru,Sugita, Kazuyuki,Hashimoto, Yuichi,Harada, Yuichi,Itamura, Shigeyuki,Odagiri, Takato,Tashiro, Masato,Sei, Yoshihisa,Yamaguchi, Kentaro,Kuzuhara, Takashi
scheme or table, p. 5379 - 5390 (2010/09/05)
Swine-origin influenza A virus has caused pandemics throughout the world and influenza A is regarded as a serious global health issue. Hence, novel drugs that will target these viruses are very desirable. Influenza A expresses an RNA polymerase essential for its transcription and replication which comprises PA, PB1, and PB2 subunits. We identified potential novel anti-influenza agents from a screen of 34 synthesized phenethylphenylphthalimide analogs derived from thalidomide (PPT analogs). For this screen we used a PA endonuclease inhibition assay, a PB2 pathogenicity-determinant domain-binding assay, and an anti-influenza A virus assay. Three PPT analogs, PPT-65, PPT-66, and PPT-67, were found to both inhibit PA endonuclease activity and retard the growth of influenza A, suggesting a correlation between their activities. PPT-28 was also found to inhibit the growth of influenza A. These four analogs have a 3,4-dihydroxyphenethyl group in common. We also discuss the possibility that 3,4-dihydroxyphenethyl group flexibility may play an important functional role in PA endonuclease inhibition. Another analog harboring a dimethoxyphenethyl group, PPT-62, showed PB2 pathogenicity-determinant domain-binding activity, but did not inhibit the growth of the virus. Our present results indicate the utility of the PA endonuclease assay in the screening of anti-influenza drugs and are therefore useful for future strategies to develop novel anti-influenza A drugs and for mapping the function of the influenza A RNA polymerase subunits.
